A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

Inclusion Criteria Concurrent Medication: Required: * PCP prophylaxis for patients with CD4 count \<= 200 cells/mm3. Allowed: * Topical antifungal agents. * Oral ketoconazole, fluconazole, and itraconazole for candidiasis or disseminated fungal infections. * Isoniazid, ethambutol, pyrazinamide, clofazimine, ciprofloxacin, and clarithromycin for acute or maintenance therapy for mycobacterial disease (also clarithromycin for MAC prophylaxis). * Acute or maintenance therapy for toxoplasmosis. * Acute or maintenance therapy with acyclovir (no more than 1000 mg/day) for herpes simplex virus infection. * rEPO and rG-CSF. * Antibiotics for bacterial infections (except rifampin and rifabutin). * Antipyretics, analgesics, nonsteroidal anti-inflammatory agents, antiemetics, and methadone. Concurrent Treatment: Allowed for cutaneous Kaposi's sarcoma: * Localized radiation therapy. * Limited intralesional therapy. Patients must have: * HIV infection. * CD4 count 100 - 500 cells/mm3. * Prior cumulative monotherapy of \<= 6 months (may have taken either AZT or ddI, but not both) OR no prior antiretroviral therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malignancy (other than basal or squamous cell carcinoma of the skin, Stage 1 or 2 cervical intraepithelial neoplasia, or minimal Kaposi's sarcoma). * Considered to be unlikely to comply with study requirements. Concurrent Medication: Excluded: * Antiretroviral therapies and biologic response modifiers (except for study medications, rEPO, and rG-CSF). * Rifampin. * Rifabutin. * Terfenadine. * Astemizole. * Loratadine. * Quinidine. * Digitoxin. * Systemic corticosteroids for more than 21 consecutive days. * Foscarnet. * Systemic cytotoxic chemotherapy for a malignancy. Patients with the following prior conditions are excluded: * History of intolerance to AZT at \<= 600 mg/day or ddI at \<= 400 mg/day or discontinuation of either drug for toxicity. * History of intolerance to trifluoperazine or piperazine citrate (per amendment). * History of pancreatitis. * History of grade 2 or worse peripheral neuropathy. * Unexplained temperature \>= 38.5 C on any 7 days within the past 30 days. * Chronic diarrhea on any 15 days during the past 30 days. Prior Medication: Excluded: * Prior foscarnet as induction or maintenance therapy. * Prior U-90152. * Prior ddC or d4T. * Prior AZT/ddI in combination or taken separately at different times. * Prior non-nucleoside reverse transcriptase inhibitors (nevirapine, atevirdine, etc.). * Prior protease inhibitors (although patients from ACTG 282 are eligible). * HIV-1 vaccine within the past 21 days. * Acute treatment for a serious infection or for any opportunistic infection within the past 14 days. Excluded within the past 30 days: * Interferon or interleukin. * Rifampin. * Rifabutin. * Terfenadine. * Astemizole. * Loratadine. * Recombinant EPO or G-CSF. * Hydroxyurea. * SPV-30. * Any other investigational drug. Active drug or alcohol use.